posted
SVA, GNBT and CBMX and NVAX! NVAX in my opinion will be huge this week. I might be wrong though. I strongly feel it has a breakout and could see 6.00 very soon. Espeacially with the flu outbreak in euroupe! Think about it once a case of bird flu is found in America. you could choose pretty much any bird flu making company because investors will start to speculate about gov. funding. I would choose NVAX and GNBT for the moment. Espeacially GNBT, current pps $1.62 they just had a meeting with the FDA about the avian drug that they are able to produce! THis is huge expect a pr soon and this could see 4.00 or 5.00 in short term! hope this helps
IP: Logged |
""The history of H5N1, as well as that for human influenza, suggests that the vaccines that provide 100% protection against the strain for which they were developed, will provide between 60% to 80% protection the following year yet diminish every year, requiring constant new vaccine development."
As a scientist, I can tell you that the above is total crap. It is not written by a scientist. Existing Flu vaccines are ineffective. The FDA only allows them bcs. of decades of whining. Any vaccine scientist would know this.
Fact: If a flu vaccine were possible, then humans would get the flu once and then recover, like measles. Its not possible right now, but we can still make money.
The above are bird flu plays. Buy SVA and GNBT.
SVA has the best chart. GNBT is a rocket. I put a $50-100 price target on both.
NNVC is a risky pinky scam. Nuff said.
NVAX is a patent play. Not bird flu. We need a vaccine.
IP: Logged |
quote:As a scientist, I can tell you that the above is total crap. It is not written by a scientist. Existing Flu vaccines are ineffective. The FDA only allows them bcs. of decades of whining. Any vaccine scientist would know this.
not defending NNVC (other than it has had a nice run), but if no such thing, what is that the gov't urges on folks every year re inluenza?
-------------------- Nashoba Holba Chepulechi Adventures in microcapitalism...
IP: Logged |
The FDA allows flu vaccines bcs. of massive public pressure. But you will not find any data that they work. Double blind studies show a negligible effect. Ask anyone that you will still get the flu. But, they dont hurt either, and people like them.
Sorry to bust your bubble. Facts are a cold thing.
IP: Logged |
I was just curios to know, is there any Drug companies which is making drug for Bird flu.
Shares must be lower than $5.00..
Please I want to invest it.
AVII [AVI Biopharma, Inc.] has already bounced above the $5 PPS you're looking for. But I think they may be the ones to watch for this. Presently $7.55PPS, up from $3 to $4 range in just a montha nd a half. Also, Not sure, but seems like I read somewhere that Cheney or Rumsfield had a hand in this company. Anyone got any info on that?
(It's also very ironic that "Avi" is latin for 'Bird'. hmmm.. )
quote:Originally posted by SuperSniper00: All I know is that when I get a flu shot I get the flu, and when I don't get a flu shot I dont get sick.
I agree!!! I often wonder if the medical industry uses "thesis / anti-thesis". Invent the solution, create the problem to be solved, sell the solution.
-------------------- Success is the ability to go from one failure to another with no loss of enthusiasm. -W. Churchill
IP: Logged |
""The history of H5N1, as well as that for human influenza, suggests that the vaccines that provide 100% protection against the strain for which they were developed, will provide between 60% to 80% protection the following year yet diminish every year, requiring constant new vaccine development."
As a scientist, I can tell you that the above is total crap. It is not written by a scientist. Existing Flu vaccines are ineffective. The FDA only allows them bcs. of decades of whining. Any vaccine scientist would know this.
Fact: If a flu vaccine were possible, then humans would get the flu once and then recover, like measles. Its not possible right now, but we can still make money.
The above are bird flu plays. Buy SVA and GNBT.
SVA has the best chart. GNBT is a rocket. I put a $50-100 price target on both.
NNVC is a risky pinky scam. Nuff said.
NVAX is a patent play. Not bird flu. We need a vaccine.
---------------------------------------------- 7 / 9 maybe ya better look again..This time with your glasses. -------------------------------------------
Viragen Reports Avian Transgenic Breakthrough: OVA(TM) System Expresses Interferon-Beta
By PR Newswire Last Update: 1/18/2006 11:00:29 AM Data provided by
Jan 18, 2006 /PRNewswire-FirstCall via COMTEX/ -- Viragen, Inc. (VRA) today announced that the Company's scientists, along with its collaborators at the Roslin Institute and Oxford BioMedica plc, have successfully achieved expression of significant quantities of the human protein, interferon beta-1a, in the whites of eggs laid by transgenic hens using the OVA(TM) System (Avian Transgenic Biomanufacturing). Interferon-beta is a key component of the human immune system and is the active ingredient in several leading multiple sclerosis (MS) therapies. These results are the first in a series of anticipated milestones demonstrating "Proof-of-Principle" with an avian-expressed version of interferon-beta, and it is expected that the OVA(TM) System will be capable of cost-effectively expressing many types of therapeutic proteins.
Viragen and Roslin are conducting avian expression studies on various protein candidates including interferon beta-1a, which is currently marketed under two competing brand names for the treatment of MS. These MS products are Avonex(R)*, marketed by Biogen Idec, and Rebif(R)**, marketed by Serono, with combined annual global sales over $2.5 billion.
The Project's Scientific Leader, Dr. Helen Sang of Scotland's Roslin Institute, commented, "We are extremely pleased to report this key advance in our program to develop a preferred platform for the production of selected biopharmaceutical proteins, having now successfully developed transgenic hens that are synthesizing significant quantities of interferon-beta as a component of their egg white. This is the second protein candidate with which we have achieved promising results, as we previously reported expression and recovery of a functional humanized antibody. As we fully characterize the interferon- beta that is recovered, both biochemically and by functional tests, we expect such results will confirm our progress."
"This is a truly remarkable achievement for our team in Scotland and represents a major event towards our goal to definitively position the OVA(TM) System as a revolutionary transgenic bio-manufacturing alternative," stated Dr. Karen Jervis, Vice President and Managing Director of Viragen (Scotland) Ltd. "We will continue to collect eggs from these hens and subsequent generations to confirm quality and quantity of the protein. In addition, we will be analyzing the carbohydrate profile of the product, which may represent another key advantage to OVA(TM)-expressed proteins. Certain biotech drugs require post-translational modifications in order that the drug retains its full efficacy and is well tolerated when used as a human therapeutic. Although we must confirm the nature of the modifications conferred by the OVA(TM) System, we are hopeful that avian transgenic production may be able to retain these beneficial modifications, which may in turn translate to a lower cost of goods and a more economical process."
While more data are required to provide a precise economic model, Viragen's President & CEO, Charles A. Rice, stressed the significance of this achievement, "We are continuing to report historic scientific breakthroughs, as we achieve the essential prerequisites to develop a viable, cost-effective, transgenic bio-manufacturing system. To imagine the potential, based on the highest expression levels we have found, it is conceivable that a small flock of a couple of hundred hens could satisfy the entire U.S. market demand for interferon beta-1a. These figures are preliminary, but certainly suggest why this technology might be so desirable to a company seeking new benefits in the manufacturing of current and future products. We congratulate our Scotland teams at VSL and the Roslin Institute for their commitment, patience, perseverance and fine work on this important project, and we look forward to even more dramatic results throughout this year."
*Avonex(R) (interferon beta-1a) is a registered trademark of Biogen Idec, Inc.
** Rebif(R) (interferon beta-1a) is a registered trademark of Serono, Inc.
Viragen has no agreements with Biogen Idec or Serono and did not collaborate with either company in connection with these avian expression studies.
About the OVA(TM) System:
Viragen holds the worldwide exclusive license to commercialize the OVA(TM) System (Avian Transgenic Biomanufacturing) as granted by the Roslin Institute (Scotland). The project is designed to develop the chicken into a pharmaceutical bioreactor, one that can meet the growing need for protein- based human therapeutics. Based on the creation of lines of transgenic hens which have been engineered to produce a target protein in their eggs using the LentiVector(R) gene delivery system licensed from Oxford BioMedica plc, this technology is being developed as an efficient and economical alternative to standard bio-manufacturing techniques, having many apparent advantages in ease of scale-up, lower costs of production and quality of product produced.
This project has been funded in part from a grant awarded by the Scottish Executive's "SPUR Plus Program", designed to support significant technological advances being made in Scotland.
About Viragen, Inc.:
With global operations in the U.S., Scotland and Sweden, Viragen is a biotechnology company engaged in the research, development, manufacture and commercialization of pharmaceutical proteins for the treatment of viral diseases and cancers. Our product portfolio includes: Multiferon(R) (multi- subtype, natural human alpha interferon) targeting a broad range of infectious and malignant diseases; and humanized monoclonal antibodies targeting specific antigens over-expressed on many types of cancers. We are also pioneering the development of Avian Transgenic Technology, with the renowned Roslin Institute, as a revolutionary manufacturing platform for the large-scale, efficient and economical production of human therapeutic proteins and antibodies.
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "expects," "potential," "suggests," "may," "should," "could" or similar expressions. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
Blue Gene Tackles Bird Flu IBM and Scripps have announced a collaboration to combat Avian flu pandemic.
By Associated Press
BOCA RATON, Fla. (AP) -- As the threat of Avian flu crosses continents, IBM Corp. and The Scripps Research Institute announced a collaborative initiative Thursday to meld science with computer technology to fight potential pandemic viruses before they become a global plague.
The goal of ''Project Check-mate'' will be to create models of potential flu pandemics, chart their courses and develop strategies to outsmart mutations.
The San Diego-based biotechnology institution will lead the research into virus pattern development while IBM will use the Blue Gene supercomputer, the world's fastest, to compute and interpret models.
Scripps and IBM already work together in California on a similar project researching HIV treatments.
Bird flu has killed at least 91 people since 2003, according to the World Health Organization. Most of the human deaths have been linked to contact with infected poultry, but experts fear the virus could mutate and spread easily among people, possibly sparking a pandemic.
''The problem is the virus changes ... so we're playing a chess game,'' said Nicholas Tsinoremas, director of informatics for Scripps Florida. ''I think we can tackle this problem.''
-------------------- Nashoba Holba Chepulechi Adventures in microcapitalism...
IP: Logged |
Alnylam shares gain on Novartis deal Avian-flu stocks move broadly higher E-mail | Print | | Disable live quotes By Val Brickates Kennedy, MarketWatch Last Update: 1:26 PM ET Feb 21, 2006
BOSTON (MarketWatch) -- Shares of avian-flu drug-developers rallied Tuesday after Swiss conglomerate Novartis announced a collaborative agreement with Alnylam Pharmaceuticals to develop new drugs to combat the deadly virus. Earlier Tuesday, Novartis (NVS : novartis a g sponsored adr News , chart, profile, more Last: 54.37-0.31-0.57%
1:27pm 02/21/2006 Add to portfolio Analyst Create alertInsider Discuss Financials Sponsored by: NVS54.37, -0.31, -0.6%) and Cambridge, Mass.-based biotechnology company Alnylam (ALNY : alnylam pharmaceuticals inc com News , chart, profile, more Last: 14.97+0.93+6.62%
1:32pm 02/21/2006 Add to portfolio Analyst Create alertInsider Discuss Financials Sponsored by: ALNY14.97, +0.93, +6.6%) said they would join to develop RNAi-based therapeutics that can be used to treat various forms of influenza, including avian flu, in humans. Financial terms were not disclosed. Alnylam's shares moved up nearly 10% at one point in the session, while Novartis traded narrowly lower throughout. Alnylam is already receiving funding from the Defense Advanced Research Projects Agency, also known as DARPA, to focus on pandemic flu therapeutics. The company hopes to apply for regulatory clearance to begin Phase I clinical trials for such a drug by the end of 2006. News of the deal likewise boosted shares of other smaller biotech companies engaged in avian-flu research. Niche vaccine makers Generex Biotechnology (GNBT : generex biotechnology cp del com News , chart, profile, more Last: 1.80+0.18+11.11%
1:32pm 02/21/2006 Add to portfolio Analyst Create alertInsider Discuss Financials Sponsored by: VICL4.43, +0.23, +5.5%) , Avant Immunotherapeutics (AVAN : avant immunotherapeutics inc com News , chart, profile, more Last: 1.96+0.12+6.52%
1:30pm 02/21/2006 Add to portfolio Analyst Create alertInsider Discuss Financials Sponsored by: AVAN1.96, +0.12, +6.5%) and Novavax (NVAX : Novavax, Inc. News , chart, profile, more Last: 4.99+0.39+8.48%
1:32pm 02/21/2006 Add to portfolio Analyst Create alertInsider Discuss Financials Sponsored by: NVAX4.99, +0.39, +8.5%) all moved higher, as did anti-viral drugmakers Hemispherx BioPharma (HEB : Hemispherx BioPharma Inc News , chart, profile, more Last: 3.60+0.46+14.65%
1:27pm 02/21/2006 Add to portfolio Analyst Create alertInsider Discuss Financials Sponsored by: HEB3.60, +0.46, +14.6%) and BioCryst Pharmaceuticals (BCRX : BioCryst Pharmaceuticals Inc News , chart, profile, more Last: 19.75+0.68+3.57%
1:32pm 02/21/2006 Add to portfolio Analyst Create alertInsider Discuss Financials Sponsored by: BCRX19.75, +0.68, +3.6%) . Generex was the biggest mover, jumping 11% to $1.80, while Novavax gained 9% to $4.99. Vical, which has a government contract to explore faster ways to produce DNA-based vaccines, moved up 6% to $4.44, and Avant was up 6% at $1.95. Hemispherx, which recently announced promising data for its drugs Ampligen and Alferon in the treatment of avian flu, rocketed 15% to $3.62, as BioCryst added 3% to $19.70.
-------------------- *I'm not a financial expert or advisor, everything stated is my opinion*
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Embarrassed]](redface.gif)
![[Big Grin]](biggrin.gif)
